Britain starts recruiting for real-world COVID antiviral trial

  • World
  • Thursday, 09 Dec 2021

FILE PHOTO: An experimental COVID-19 treatment pill called molnupiravir being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters May 17, 2021. Merck & Co Inc/Handout via REUTERS/Files

LONDON (Reuters) - British researchers on Wednesday started recruitment for a clinical trial to test antiviral COVID-19 treatments for use in people early on in the disease who are at higher risks of complications, starting with Merck's molnupiravir.

Britain became the first country in the world to approve molnupiravir, which was jointly developed by U.S.-based Merck & Co Inc and Ridgeback Biotherapeutics, in November.

Subscribe now to our Premium Plan for an ad-free and unlimited reading experience!

Next In World

Canadian province changes LGBT policy in schools to 'recognize role of parents'
Colombia attorney general's office investigating Petro campaign financing
Serbians take to streets in anti-government protests following mass shootings
Russia maintains key interest rate at 7.5 pct
U.S. dollar ticks up
WTI crude futures settle lower
Gold falls in correction
Bomb blast targets popular restaurant in Somali capital
Ethiopia's tree planting initiative to have 31 bln seedlings planted: PM
Britain's Labour Party to return donation to Algebris CEO following harassment claim - official

Others Also Read